Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine ER for Cough in Idiopathic Pulmonary Fibrosis
2023-505296-72-00Phase 2Completed
- Sponsor
- Trevi Therapeutics
- Start
- Nov 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of nalbuphine in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Trevi Therapeutics. Primary endpoint: 24-hour cough frequency change at Week 6. Started Nov 2023; status: completed.
02
Drugs
nalbuphine
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2023-505296-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505296-72-00.